Last updated on April 2019

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Other Details:

For more information, please contact Incyte Corporation at 1.855.463.3463

Find a site near you

Start Over

Meir Medical Center

Located in: Kfar-Saba, Israel
  Connect »

Chaim Sheba Medical Center

Located in: Ramat Gan, Israel
  Connect »

Tel Aviv Sourasky Medical Center

Located in: Tel Aviv-Yafo, Tel Aviv-Yafo Israel
  Connect »

Research Center

Located in: Ramat Gan, Israel
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.